Biostem Technologies (BSEM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BSEM Profit Margin, ROE & Profitability Analysis
BSEM vs Healthcare Sector: How Biostem Technologies Compares
How Biostem Technologies compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biostem Technologies Stock Overvalued? BSEM Valuation Analysis 2026
Based on fundamental analysis, Biostem Technologies has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biostem Technologies Balance Sheet: BSEM Debt, Cash & Liquidity
BSEM Revenue Growth, EPS Growth & YoY Performance
BSEM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biostem Technologies (CIK: 0001658678)
❓ Frequently Asked Questions about BSEM
What is the AI rating for BSEM?
Biostem Technologies (BSEM) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BSEM's key strengths?
Claude: Analysis in progress.
What are the risks of investing in BSEM?
Claude: Analysis in progress.
What is BSEM's revenue and growth?
Biostem Technologies reported revenue of N/A.
Does BSEM pay dividends?
Biostem Technologies does not currently pay dividends.
Where can I find BSEM SEC filings?
Official SEC filings for Biostem Technologies (CIK: 0001658678) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BSEM's EPS?
Biostem Technologies has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BSEM's fundamental grade?
Based on our AI fundamental analysis in May 2026, Biostem Technologies has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BSEM stock overvalued or undervalued?
Valuation metrics for BSEM: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BSEM's AI grade for 2026?
Our dual AI analysis gives Biostem Technologies a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BSEM's free cash flow?
Biostem Technologies's operating cash flow is N/A, with capital expenditures of N/A.
How does BSEM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).